IntroductionNeutralizing antibodies (Abs) are one of the immune components required to protect against viral infections. However, developing vaccines capable of eliciting neutralizing Abs effective against a broad array of HIV-1 isolates has been an arduous challenge.ObjectiveThis study sought to test vaccines aimed to induce Abs against neutralizing epitopes at the V1V2 apex of HIV-1 envelope (Env).MethodsFour groups of rabbits received a DNA vaccine expressing the V1V2 domain of the CRF01_AE A244 strain on a trimeric 2J9C scaffold (V1V2-2J9C) along with a protein vaccine consisting of an uncleaved prefusion-optimized A244 Env trimer with V3 truncation (UFO-BG.ΔV3) or a V1V2-2J9C protein and their respective immune complexes (ICs). These I...
Elicitation of broadly neutralizing antibodies (bnAbs) is a goal of vaccine design as a strategy for...
Prophylactic HIV vaccines must elicit antibodies (Abs) against the virus envelope glycoproteins (Env...
The HIV-1 envelope glycoprotein (Env) trimer is the key target for vaccines aimed at inducing neutra...
IntroductionNeutralizing antibodies (Abs) are one of the immune components required to protect again...
Strong antibody (Ab) responses against V1V2 epitopes of the human immunodeficiency virus type 1 (HIV...
Since its discovery in 1981, HIV-1 has infected almost 78 million people, and ~39 million people hav...
Developing a vaccine that overcomes the diversity of HIV-1 is likely to require a strategy that dire...
Thesis (Ph.D.)--University of Washington, 2020With more that 37 million people currently infected wi...
Prophylactic HIV vaccines must elicit antibodies (Abs) against the virus envelope glycoproteins (Env...
Prophylactic HIV vaccines must elicit antibodies (Abs) against the virus envelope glycoproteins (Env...
Prophylactic HIV vaccines must elicit antibodies (Abs) against the virus envelope glycoproteins (Env...
AbstractStudies were performed to induce cross-clade neutralizing antibodies (Abs) by testing variou...
Abstract An effective human immunodeficiency virus type I (HIV-1) vaccine that robustly elicits broa...
Evidence from active and passive vaccination trials suggests that both non-neutralizing and neutrali...
The high viral diversity of HIV-1 is a formidable hurdle for the development of an HIV-1 vaccine. El...
Elicitation of broadly neutralizing antibodies (bnAbs) is a goal of vaccine design as a strategy for...
Prophylactic HIV vaccines must elicit antibodies (Abs) against the virus envelope glycoproteins (Env...
The HIV-1 envelope glycoprotein (Env) trimer is the key target for vaccines aimed at inducing neutra...
IntroductionNeutralizing antibodies (Abs) are one of the immune components required to protect again...
Strong antibody (Ab) responses against V1V2 epitopes of the human immunodeficiency virus type 1 (HIV...
Since its discovery in 1981, HIV-1 has infected almost 78 million people, and ~39 million people hav...
Developing a vaccine that overcomes the diversity of HIV-1 is likely to require a strategy that dire...
Thesis (Ph.D.)--University of Washington, 2020With more that 37 million people currently infected wi...
Prophylactic HIV vaccines must elicit antibodies (Abs) against the virus envelope glycoproteins (Env...
Prophylactic HIV vaccines must elicit antibodies (Abs) against the virus envelope glycoproteins (Env...
Prophylactic HIV vaccines must elicit antibodies (Abs) against the virus envelope glycoproteins (Env...
AbstractStudies were performed to induce cross-clade neutralizing antibodies (Abs) by testing variou...
Abstract An effective human immunodeficiency virus type I (HIV-1) vaccine that robustly elicits broa...
Evidence from active and passive vaccination trials suggests that both non-neutralizing and neutrali...
The high viral diversity of HIV-1 is a formidable hurdle for the development of an HIV-1 vaccine. El...
Elicitation of broadly neutralizing antibodies (bnAbs) is a goal of vaccine design as a strategy for...
Prophylactic HIV vaccines must elicit antibodies (Abs) against the virus envelope glycoproteins (Env...
The HIV-1 envelope glycoprotein (Env) trimer is the key target for vaccines aimed at inducing neutra...